Novo Nordisk announced that it is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity. Wegovy®?

pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy®? is backed by proven results, as millions have been prescribed Wegovy®?

(semaglutide) injection 2.4 mg for weight management since 2021. Wegovy®?®? pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials, boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.

When looking at the efficacy regardless of if all patients stayed On treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy®? pill compared to about 2% (2.4%) for placebo. With once-daily oral dosing, Wegovy®?

pill can provide patients with a practical option as part of their daily routine to help people achieve meaningful weight loss. Wegovy®? Pill 25 mg Placebo.

percentage weight If all patients stayed on treatment ~17% ~3% reduction at 64 weeks1 (Trial product estimand). Analysis of all patients regardless ~14% ~2% of if they stayed on treatment (T Treatment policy estimand). For Wegovy®?

pill based on baseline body weight of 235 lb., and for placebo based on baseline body weight of 231 lb. In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy®? (SEmaglutide) injection2.4 mg, including nausea, diarrhea, and vomiting.

NovoCare®? continues to pursue innovative delivery models and strategic collaborations to meet people where they are, reaching more patients in more ways. This is designed to help patients obtain authentic, FDA-approved medicines and avoid potentially unsafe, unapproved alternatives.

Wegovy®? are available through a range of options including US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare®? Pharmacy, GoodRx and others.

NovoCare®? reserves the right to modify or cancel this program at any time. Wegovy®?

pills is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease. The FDA approval of Wegovy®? pill is based on the results from the OASIS 4 phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related diseases, without diabetes.

Perceptions of barriers to effective obesity care: results from the national action study.